ArticleBMC pregnancy and childbirth2025
Clinical characteristics, pregnancy outcomes, and neonatal effects of cytomegalovirus infection in pregnant women in Liuzhou city, North central Guangxi of Southern China: a retrospective study from 2018 to 2024.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and genetic analysis of different Dandy-Walker malformation.BMC pregnancy and childbirth · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveTo evaluate the clinical characteristics, pregnancy and neonatal outcomes of cytomegalovirus (CMV) infection in pregnant women.
methodsThis retrospective study included 22,673 pregnant women from Liuzhou, Guangxi, China, between 2018 and 2024. Amniotic fluid samples collected during mid-to-late pregnancy were tested for CMV DNA. Clinical data among CMV-infected pregnant women were collected, including prenatal diagnosis indicators, early-pregnancy CMV antibodies, pregnancy and neonatal outcomes, and offspring follow-up outcomes.
resultsAmong 22,673 pregnant women, 36 (1.59‰) were tested positive for CMV DNA in amniotic fluid, among which 14 (38.9%) with adverse pregnancy outcomes, including 7(19.4%) termination of pregnancy, 3(8.3%) stillbirth and 4 (11.1%) preterm delivery. Prenatal imaging modalities detected fetal abnormalities 21 (58.3%) in the CMV-infected pregnant women, mainly were ventriculomegaly, fetal growth restriction (FGR), pericardial effusion, ascites, cardiomegaly, placentomegaly, enlarged cisterna magna and hyperechogenic bowel. Notably, Fetuses of 2 pregnant women with primary CMV infection developed severe edema. Four newborns failed with initial hearing screening during postnatal evaluation. Among them, two (50%) were diagnosed with severe sensorineural hearing loss (SNHL) and one child was diagnosed with cerebral palsy in subsequent clinical assessments.
conclusionDiagnosis of primary CMV infection during pregnancy is of critical importance. Current guidelines recommend implementing CMV serological screening during the first trimester, with subsequent CMV IgG avidity testing when CMV IgG antibodies are detected. Maternal CMV infection during the second and third trimesters may lead to fetal complications, including ventriculomegaly, FGR and fetal hydrops. Congenital CMV (cCMV) infection predominantly manifests with sensorineural hearing loss (SNHL) and cerebral palsy. It is essential to screen all neonates from CMV-infected pregnant women for CMV DNA and provide mandatory 5-year follow-up for symptomatic cCMV children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.